Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr:105:686-687.
doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15.

Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al

Zarir F Udwadia  1 , Hanmant Barkate  2 , Saiprasad Patil  2 , Shabbir Rangwala  2 , Wen Wu  3 , Cynthia F Caracta  4 , Monika Tandon  5
Affiliations
Comment

Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al

Zarir F Udwadia et al. Int J Infect Dis. 2021 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764. - DOI - PMC - PubMed
    1. Heneghan C.J., Onakpoya I., Jones M.A., Doshi P., Del Mar C.B., Hama R. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1–242. - PMC - PubMed
    1. https://clinicaltrials.gov/ct2/show/NCT04346628.
    1. https://clinicaltrials.gov/ct2/show/NCT04252664.
    1. Lachin J.M., Foulkes M.A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42:507–519. - PubMed